127 related articles for article (PubMed ID: 21881039)
1. Elucidating an uncommon disease: inflammatory breast cancer.
Crane K
J Natl Cancer Inst; 2011 Sep; 103(18):1358-60. PubMed ID: 21881039
[No Abstract] [Full Text] [Related]
2. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
3. Case records of the Massachusetts General Hospital. Case 16-2012. A 32-year-old woman with HER2-positive breast cancer.
Baselga J; Smith BL; Rafferty EA; Bombonati A
N Engl J Med; 2012 May; 366(21):2018-26. PubMed ID: 22621630
[No Abstract] [Full Text] [Related]
4. Trimodal therapy for inflammatory breast cancer: a surgeon's perspective.
Li BD; Sicard MA; Ampil F; Abreo F; Lilien D; Chu QD; Burton GV
Oncology; 2010; 79(1-2):3-12. PubMed ID: 21051912
[TBL] [Abstract][Full Text] [Related]
5. An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer.
Bonnefoi H; Zaman K; Debled M; Fiche M; Fournier M; Nobahar M; Pierga JY; Koch KM; Bartlett J; Zimmer A; Marreaud S; Bogaerts J; Cameron D
Eur J Cancer; 2013 Jan; 49(2):281-9. PubMed ID: 22999386
[TBL] [Abstract][Full Text] [Related]
6. [HER2-positive breast cancer: standard and double targeted therapy].
Semiglazov VF; Bozhok AA; Semiglazova TIu; Vasil'ev AG; Manikhas AG; Semiglazov VV; Bessonov AA; Nikolaev KS
Vopr Onkol; 2013; 59(3):341-6. PubMed ID: 23909035
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance imaging in predicting pathological response of triple negative breast cancer following neoadjuvant chemotherapy.
Chen JH; Mehta RS; Carpenter PM; Nalcioglu O; Su MY
J Clin Oncol; 2007 Dec; 25(35):5667-9. PubMed ID: 18065744
[No Abstract] [Full Text] [Related]
8. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.
Coudert BP; Largillier R; Arnould L; Chollet P; Campone M; Coeffic D; Priou F; Gligorov J; Martin X; Trillet-Lenoir V; Weber B; Bleuse JP; Vasseur B; Serin D; Namer M
J Clin Oncol; 2007 Jul; 25(19):2678-84. PubMed ID: 17515572
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy and targeted therapies: a promising strategy.
Metzger-Filho O; de Azambuja E
J Natl Cancer Inst Monogr; 2011; 2011(43):116-9. PubMed ID: 22043056
[TBL] [Abstract][Full Text] [Related]
11. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
Yaal-Hahoshen N; Safra T
Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
[No Abstract] [Full Text] [Related]
12. Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer.
Altundag K; Baptista MZ
Breast J; 2006; 12(5):497-8. PubMed ID: 16958977
[No Abstract] [Full Text] [Related]
13. Hints of future progress for HER-2 breast cancer.
Twombly R
J Natl Cancer Inst; 2011 Apr; 103(7):535-7. PubMed ID: 21436059
[No Abstract] [Full Text] [Related]
14. [Strategies of breast cancer treatment based on determination of biological subtype].
Semiglazov VF
Vopr Onkol; 2011; 57(5):542-52. PubMed ID: 22238922
[No Abstract] [Full Text] [Related]
15. [Case of a patient with inflammatory breast cancer who responded to preoperative chemotherapy with paclitaxel plus bevacizumab and could subsequently undergo surgery].
Kashiwagi S; Ishihara S; Ishii M; Asano Y; Watanabe M; Morisaki T; Aomatsu N; Noda S; Kawajiri H; Nakano T; Kawakami N; Mitsukawa Y; Takashima T; Onoda N; Ishikawa T; Hirakawa K
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2384-6. PubMed ID: 24394120
[TBL] [Abstract][Full Text] [Related]
16. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
17. Patients with anti-HER2 responsive disease: definition and adjuvant therapies.
Burstein HJ
Breast; 2011 Oct; 20 Suppl 3():S132-4. PubMed ID: 22015280
[TBL] [Abstract][Full Text] [Related]
18. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)].
Sawaki M; Tokudome N; Mizuno T; Nakayama T; Taira N; Bando H; Murakami S; Yamamoto Y; Kashiwaba M; Iwata H; Uemura Y; Ohashi Y
Jpn J Clin Oncol; 2011 May; 41(5):709-12. PubMed ID: 21355003
[TBL] [Abstract][Full Text] [Related]
20. Treatment of breast cancer with trastuzumab during pregnancy.
Pant S; Landon MB; Blumenfeld M; Farrar W; Shapiro CL
J Clin Oncol; 2008 Mar; 26(9):1567-9. PubMed ID: 18349415
[No Abstract] [Full Text] [Related]
[Next] [New Search]
